Both axillary lymph node dissection and axillary radiotherapy provide excellent regional control for breast cancer patients with a positive sentinel node biopsy, shows Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial.
The AMAROS trial also found that axillary radiotherapy reduces the risk of short term and long-term lymphoedema as compared to axillary lymph node dissection.
Breast Lesion and Breast Cancer, Now Detected by the Same Test
A new single step Raman spectroscopy algorithm may simultaneously detect breast lesions and breast cancer, a new study shows
Advertisement
Prof. Emiel J. Rutgers of The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis in Amsterdam, the EORTC Breast Cancer Group, and principal investigator of this study says, "Sentinel node biopsy has become the standard procedure for assessing axillary lymph node status for cN0 breast cancer patients. At the start of this trial the question was whether axillary lymph node dissection should remain the standard treatment in case of a tumor positive sentinel node."
From 2001 to 2010, 4806 patients who were diagnosed with invasive breast cancer were enrolled in this phase III non-inferiority trial, and randomized for their axillary treatment in case the sentinel node biopsy was positive. Of these, 3131 patients had negative biopsies and 250 patients had a different sentinel node outcome. Thus, out of 1425 patients with positive node, axillary lymph node dissection was to be used in 744 patients, and axillary radiotherapy in 681 patients.
![Genetic Marker for Sporadic Breast Cancer Identified by U of A Medical Researchers]( "Genetic Marker for Sporadic Breast Cancer Identified by U of A Medical Researchers")
A genetic marker for sporadic breast cancer has been identified by medical researchers at the University of Alberta.
Dr. Geertjan van Tienhoven of the Academisch Medisch Centrum - Universiteit van Amsterdam and principal investigator on behalf of the EORTC Radiation Oncology Group says, "Although axillary lymph node dissection provides excellent regional control, it was known to cause harmful side effects. Axillary radiotherapy instead of axillary lymph node dissection was hypothesized to provide comparable regional control and perhaps fewer side effects in this particular group of patients."
The primary endpoint of this EORTC trial was 5-year axillary recurrence rate. At a median follow up of 6.1 years, this rate was 0.54% (4 out of 744 patients) after axillary lymph node dissection and 1.03% (7 out of 681 patients) after axillary radiotherapy. Due to the unexpectedly low number of events, the non-inferiority test was underpowered. The axillary recurrence rate for patients with a negative sentinel node biopsy was 0.8% (25 out of 3131 patients).
Secondary endpoints were overall survival, disease-free survival, quality of life, shoulder movement and lymphoedema at one and five years. No significant differences in overall or disease free survival were observed between the two treatment arms. Five year estimates for overall survival were 93.3% for the arm receiving axillary lymph node dissection and 92.5% for patients in the axillary radiotherapy arm (p=0.34), and fordisease-free survival the five year estimates were 86.9% for axillary lymph node dissection and 82.6% for axillary radiotherapy (p=0.18).
Lymphoedema, a swelling of tissue (typically occurring in the arm), occurred more often following axillary lymph node dissection, 40% at one year and 28% at five years, than after axillary radiotherapy, 22% at one year and 14% at five years (p<0.0001) There was a trend, albeit non-significant, towards more impairment of shoulder movement in the first year after axillary radiotherapy.
Both results were compatible with two patient reported quality of life items in the arm symptom scale: swelling, where patients in the axillary radiotherapy fared better, and mobility, where patients in the axillary lymph node dissection arm fared better.
In this group of breast cancer patients with a metastasis in the sentinel node, radiotherapy of the axilla instead of surgery provides excellent regional control. Axillary radiotherapy reduces the risk of short term and long-term lymphoedema compared to axillary lymph node dissection.
Source: Eurekalert
Genetic Marker for Sporadic Breast Cancer Identified by U of A Medical Researchers
A genetic marker for sporadic breast cancer has been identified by medical researchers at the University of Alberta.
Advertisement
Dr. Geertjan van Tienhoven of the Academisch Medisch Centrum - Universiteit van Amsterdam and principal investigator on behalf of the EORTC Radiation Oncology Group says, "Although axillary lymph node dissection provides excellent regional control, it was known to cause harmful side effects. Axillary radiotherapy instead of axillary lymph node dissection was hypothesized to provide comparable regional control and perhaps fewer side effects in this particular group of patients."
The primary endpoint of this EORTC trial was 5-year axillary recurrence rate. At a median follow up of 6.1 years, this rate was 0.54% (4 out of 744 patients) after axillary lymph node dissection and 1.03% (7 out of 681 patients) after axillary radiotherapy. Due to the unexpectedly low number of events, the non-inferiority test was underpowered. The axillary recurrence rate for patients with a negative sentinel node biopsy was 0.8% (25 out of 3131 patients).
Secondary endpoints were overall survival, disease-free survival, quality of life, shoulder movement and lymphoedema at one and five years. No significant differences in overall or disease free survival were observed between the two treatment arms. Five year estimates for overall survival were 93.3% for the arm receiving axillary lymph node dissection and 92.5% for patients in the axillary radiotherapy arm (p=0.34), and fordisease-free survival the five year estimates were 86.9% for axillary lymph node dissection and 82.6% for axillary radiotherapy (p=0.18).
Lymphoedema, a swelling of tissue (typically occurring in the arm), occurred more often following axillary lymph node dissection, 40% at one year and 28% at five years, than after axillary radiotherapy, 22% at one year and 14% at five years (p<0.0001) There was a trend, albeit non-significant, towards more impairment of shoulder movement in the first year after axillary radiotherapy.
Both results were compatible with two patient reported quality of life items in the arm symptom scale: swelling, where patients in the axillary radiotherapy fared better, and mobility, where patients in the axillary lymph node dissection arm fared better.
In this group of breast cancer patients with a metastasis in the sentinel node, radiotherapy of the axilla instead of surgery provides excellent regional control. Axillary radiotherapy reduces the risk of short term and long-term lymphoedema compared to axillary lymph node dissection.
Source: Eurekalert
Mastectomy Popular in Young Breast Cancer Patients
A new research on young women revealed that most of them suffering from breast cancer prefer to undergo a mastectomy rather than a surgical procedure that would conserve the breast
Advertisement
 Non-Surgical Breast Cancer Therapy Trial Underway in JapanThe first clinical trial to test the effectiveness of a powerful, non-surgical, short-term radiation therapy for breast cancer has been started by a cancer specialist in Japan. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
The discovery deepens our understanding of m6A biology and stress granule formation, with implications for neurodegenerative diseases.
Trouble with sleep and the body's clock may increase your risk for Parkinson's, as per a new study.
New study uncovers a link between nocturnal hot flashes and Alzheimer's risk in menopausal women, suggesting a potential biomarker.
Our discovery revealed that a minority of individuals attributed their chronic pain to their brain's involvement.
Relative Energy Deficiency in Sport syndrome is overlooked by athletes and can be worsened by 'sports culture' due to its perceived short-term performance benefits.
